Articles By Audrey Gibson, MsPAS, PA-C
ICYMI: Are GLP-1s Doing More Than Shrinking Waistlines in PsA?
We have spent years telling patients with PsA that weight loss may improve symptoms and reduce cardiometabolic risk. A new ACR 2026 abstract asks the more provocative question: could GLP-1–based therapy influence PsA outcomes even after accounting for the change on the scale?
Read Article
Are GLP-1s Doing More Than Shrinking Waistlines in PsA?
We have spent years telling patients with PsA that weight loss may improve symptoms and reduce cardiometabolic risk. A new ACR 2026 abstract asks the more provocative question: could GLP-1–based therapy influence PsA outcomes even after accounting for the change on the scale?
Read ArticleThe PsA Weight-Loss Treatment Gap: Are We Missing the Bigger Picture?
Among the groundbreaking clinical trials and new treatment strategies, one of the most important stories may be about something we aren't doing enough of: addressing obesity and cardiometabolic risk in our patients with psoriatic arthritis (PsA).
Read Article
Paradoxical Reactions, Target Selection & the Future of Imaging in Psoriatic Care
From paradoxical psoriasis to IL-23 vs IL-17 to imaging in PsA, speakers in RheumNow Live's "Decisions in Psoriatic Arthritis" pod delivered valuable, clinically relevant education.
Read Article
Prevention in Lupus and Therapeutic Evolution in Sjögren’s
The notion of intervening in autoimmune disease prior to the onset of irreversible tissue damage has evolved beyond a theoretical framework; it is presently undergoing empirical evaluation. Recent discussions on incomplete lupus and the SMILE trial, alongside advances in Sjögren’s therapeutics, highlight both the promise and complexity of prevention and precision treatment in systemic autoimmunity.
Read Article
Disease Modification, Disparities and the Next Therapeutic Frontier in Gout
Gout management has entered what Dr. Robert Terkeltaub MD from UC San Diego described as its “disease-modifying era,” during his talk at RheumNow Live 2026. In a recent comprehensive review of the past, present, and future of gout therapy, the central message was clear: “We can really apply disease modification to gout based on prospective, randomized controlled trials.”
Read Article
